Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE

医学 不利影响 临床试验 梅德林 皮肤病科 外科 内科学 政治学 法学
作者
Geoffrey Alan Watson,Zachary Veitch,Daniel Shepshelovich,Zhihui Amy Liu,Anna Spreafico,Albiruni R. Abdul Razak,Philippe L. Bédard,Lillian L. Siu,Lori M. Minasian,Aaron R. Hansen
出处
期刊:British Journal of Cancer [Springer Nature]
卷期号:127 (9): 1629-1635 被引量:4
标识
DOI:10.1038/s41416-022-01926-z
摘要

Adverse event (AE) reporting in early-phase clinical trials is essential in determining the tolerability of experimental anticancer therapies. The patient-reported outcome version of the CTCAE (PRO-CTCAE) evaluates AE components such as severity and interference in daily life. The aim of this study was to correlate the grade of clinician-reported AEs with patients' reported experience of these toxicities using PRO-CTCAE. Patients with advanced solid tumours enrolled on Phase I clinical trials were surveyed using the PRO-CTCAE. Symptomatic AEs were recorded by physicians using the CTCAE. A logistic regression model was used to assess associations between CTCAE grade and PRO responses. Of 219 evaluable patients, 81 experienced a high-grade (3/4) clinician-reported symptom, and of these, only 32 (40%) and 26 (32%) patients concordantly reported these as either severe or very severe, and interfering with daily life either 'quite a bit' or 'very much', respectively. Of the 137 patients who experienced a low-grade (1/2) clinician-reported AE as their worst symptom, 98 (72%) and 118 (86%) patients concordantly reported these as either mild–moderate severity and minimally interfering with daily life, respectively. There was a statistically significant association between clinician-reported AE grade and interference. Interference scores were also associated with dose reductions. This is the first study to explore patient-reported severity and interference from symptomatic toxicities and compare clinician grading of the same toxicities. The study provided further evidence to support the added value of the PRO-CTCAE in Phase I oncology trials, which would make AE reporting patient-centred. Further work is needed to determine how this would affect the assessment of tolerability.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王霖发布了新的文献求助20
1秒前
324完成签到 ,获得积分10
1秒前
kfy发布了新的文献求助10
1秒前
在水一方的应助被标致鹤轩采纳,获得10
1秒前
结实的胡萝卜完成签到,获得积分10
1秒前
哦哦啊啊啊完成签到,获得积分10
1秒前
NexusExplorer的应助被viviyoung采纳,获得10
2秒前
luo完成签到 ,获得积分10
2秒前
Jessica完成签到,获得积分10
2秒前
mm发布了新的文献求助30
2秒前
syvshc的应助被hahahaha采纳,获得10
3秒前
马宇恒发布了新的文献求助10
3秒前
英俊的铭的应助被happy采纳,获得10
3秒前
小豆爱科研完成签到,获得积分10
3秒前
武丝丝完成签到,获得积分10
4秒前
奇点完成签到 ,获得积分10
4秒前
鱼鱼完成签到 ,获得积分10
5秒前
2425完成签到,获得积分10
5秒前
5秒前
科研通AI6.4的应助被桩桩采纳,获得10
5秒前
流云完成签到,获得积分10
6秒前
6秒前
youyou完成签到,获得积分10
6秒前
7秒前
7秒前
Akim的应助被你是我的唯一采纳,获得10
8秒前
乐观小猫咪完成签到,获得积分10
8秒前
Yuanzhi完成签到,获得积分10
8秒前
CodeCraft的应助被科研通管家采纳,获得10
9秒前
斯文败类的应助被科研通管家采纳,获得10
9秒前
科研小能手的应助被科研通管家采纳,获得100
9秒前
英姑的应助被冷面桃花采纳,获得10
9秒前
秋风的应助被科研通管家采纳,获得10
9秒前
在水一方的应助被科研通管家采纳,获得20
9秒前
慕青的应助被科研通管家采纳,获得10
10秒前
aajhajkahna的应助被科研通管家采纳,获得10
10秒前
顾矜的应助被科研通管家采纳,获得10
10秒前
小二郎的应助被科研通管家采纳,获得10
10秒前
大模型的应助被科研通管家采纳,获得10
10秒前
wanci的应助被Kevin丶大牛采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185801
求助须知:如何正确求助?哪些是违规求助? 9574479
关于积分的说明 21836390
捐赠科研通 7783594
什么是DOI,文献DOI怎么找? 3434671
关于科研通互助平台的介绍 2559029
邀请新用户注册赠送积分活动 2481466